Now Playing
|Videos|March 3, 2017
Navigating a Colon Cancer Journey
Advertisement
Episodes in this series
Advertisement
Related to this article
In the phase 3 ASAC trial, daily aspirin did not lower the risk of colorectal cancer returning after treatment for liver metastases, and serious side effects were more common.
The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.
Advertisement
Advertisement
Trending on CURE
1
Why PSA Monitoring Matters After a Prostate Cancer Diagnosis
2
FDA Withdraws Zepzelca Approval for Previously Treated Small Cell Lung Cancer
3
Life After Cancer: Challenge Yourself to Build Healthier Habits and Stronger Relationships
4
The Cancer Search Bar: Top Lung Cancer Surgery Questions Answered
5